Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Integrating information across datasets to improve prognostic models for patients with diffuse large B-cell lymphoma.

Created on 19 Nov 2026

Authors

Can Xie, Dai Chihara, R Andrew Harkins, Ruosha Li, Xuelin Huang, Christopher R Flowers

Published in

Haematologica. Nov 19, 2026. Epub Nov 19, 2026.

Abstract

Accurate survival prediction is vital for guiding clinical decisions in diffuse large B-cell lymphoma (DLBCL), especially for advancing precision medicine within its genomically heterogeneous subgroups. However, datasets that include both detailed clinical variables and genomic profiling are usually small. In contrast, large population-based datasets often lack multiomics data. This gap limits the development and validation of robust prognostic models in DLBCL. We developed a transfer-learning prognostic framework that leverages the external population-level information from the Surveillance, Epidemiology, and End Results program to the prognostic model for an individual-level clinical and genomic cohort. The proposed model is a Cox-model-based boosted regression with individual data for generalization and enhancement (BRIDGE-Cox) that increases predictive accuracy and reduces uncertainty. The BRIDGE-Cox model incorporates the International Prognostic Index (IPI) factors, with model training performed in the Reddy genomic dataset and external validation in an independent National Cancer Institute genomic dataset. Compared with conventional IPI-based and revised IPI-based Cox models, the BRIDGE-Cox model improved predictive performance for overall survival, achieving a higher concordance index (0.70 vs 0.66 and 0.63, respectively) and consistently higher time-dependent area under the receiver operating characteristic curves for 2-, 3-, and 5- year survival prediction by using the repeated cross-validation in the Reddy dataset. Importantly, these gains were maintained within genomic subgroups. External validation confirmed the robustness and generalizability of the BRIDGE-Cox approach. By borrowing large populationlevel data, this model addresses key limitations of existing tools and enables more reliable risk stratification for patients with DLBCL, particularly in genomically defined subpopulations.

PMID:
43053711
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement